RevMed’s pancreatic cancer pill priced above $475,000 a year

Revolution Medicines Inc. won U.S. approval for a breakthrough pill that lengthens the lives of patients with advanced pancreatic cancer, a major advance against one of the hardest-to-treat tumor types.